

June 3, 2019

Dear Shareholders

Christophe Weber  
President and Representative Director  
Takeda Pharmaceutical Company Limited  
1-1, Doshomachi 4-chome  
Chuo-ku, Osaka

Partial Correction to the Notice of Convocation of the 143rd Ordinary General Meeting  
of Shareholders

Takeda Pharmaceutical Company Limited (the “Company”) hereby reports that there are parts to be corrected in the Notice of Convocation of the 143rd Ordinary General Meeting of Shareholders (the “Notice”) and that the Company therefore decided to make corrections to the said parts as described herein below.

1. Correction parts:

- (i) “Total amounts of compensation, etc.” shown in the table of “The total amounts of compensation, etc., for Directors for this fiscal year (not including the bonuses and the salaries and bonuses paid to the relevant Directors for their work as employees)” and (ii) Notes 2 [2] thereof, both of which are in Paragraph (3) “Compensation, etc. for Directors” of Item 4 “Executives of the Company” of the Business Report attached to the Notice set forth on pages 87 through 89 of the Notice

2. Contents of the correction:

[After correction]

(Underlined sections indicate changes)

Category	Number of people	Total amounts of compensation, etc. * * Basic compensation and cost postings relating to the stock compensation
Directors who are not Audit and Supervisory Committee Members (External Directors)	12 (8)	<u>1,411</u> million JPY (178 million JPY)
Directors who are Audit and Supervisory Committee Members (External Directors)	4 (3)	137 million JPY (87 million JPY)

(Notes) 2 <Omitted>

- [2] The cost posting relating to stock compensation is the value posted during this fiscal year (963 million JPY, which includes the 61 million JPY for External Directors).  
<The rest is omitted>

[Before correction]

(Underlined sections indicate changes)

Category	Number of people	Total amounts of compensation, etc. * * Basic compensation and cost postings relating to the stock compensation
Directors who are not Audit and Supervisory Committee Members (External Directors)	12 (8)	<u>1,262</u> million JPY (178 million JPY)
Directors who are Audit and Supervisory Committee Members (External Directors)	4 (3)	137 million JPY (87 million JPY)

(Notes) 2 <Omitted>

[2] The cost posting relating to stock compensation is the value posted during this fiscal year (814 million JPY, which includes the 61 million JPY for External Directors).  
<The rest is omitted>

[End of document]